ABSTRACT

It's very uncommon for people with NAFLD and T2DM to have one or the other, and this may have a negative impact on their health. Having NAFLD with T2DM raises the chance of developing diabetic complications (including macro- and micro vascular problems) and of having a more severe NAFLD (including cirrhosis, hepatocellular carcinoma and mortality). Currently, the primary goal of NAFLD treatment is to decrease patient's observable metabolic risk. Glycemic management and weight reduction optimization are critical for slowing disease development. As soon as cirrhosis develops, it's critical to monitor for problems and take steps to prevent further liver damage. NAFLD patients presently have few treatment choices for changing their condition. While there are published data on the best oral hypoglycaemic medication or injectable treatment for people with diabetes and NAFLD, most of these data come from retrospective series and well-designed randomised double blind placebo controlled trials with gold-standard end goals are few. As a result, it is difficult to make general findings that can be applied to all people with NAFLD and diabetes. Here, we have summarised and analysed the existing evidence in an effort to assist readers become more knowledgeable when it comes to dealing with patients who have NAFLD and T2DM both co-occurring. Keywords: NAFLD, NASH, Diabetes, Insulin resistance, Diabetes complications
Publication date: 15/12/2021

https://ijbpas.com/pdf/2021/December/MS_IJBPAS_2021_DEC_SPCL_1007.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2021/10.12.1007